Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Industry:MED PRODUCTS Sector: Medical Fiscal Year End:December Last Reported Quarter:03/31/12 Next EPS Date:05/23/12
Capital Structure Solvency and Cash Flow
Trading cash flow (defined as cash generated from operations less capital expenditure but before acquisition related costs and restructuring and rationalization costs) was $205 million in 3Q10, reflecting a trading profit to cash conversion ratio of 95%, compared with 89% in the sequentially prior quarter. This continued improvement partly reflects the company’s focus on tighter inventory management.
Net debt decreased in 3Q10 to $600 million from $720 million in 2Q10.
Last edited Fri Dec 24, 2010 05:55 AM by MadhubantiMaitra (Zacks Investment Research)
Governance Social Responsibility and Employee Relations
